Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

MAYNE PHARMA GROUP LIMITED Capital/Financing Update 2012

Dec 6, 2012

65396_rns_2012-12-06_f47a58a4-9968-4b33-9e0f-e880c9ab1119.pdf

Capital/Financing Update

Open in viewer

Opens in your device viewer

==> picture [199 x 117] intentionally omitted <==

7 December 2012

Manager, Company Announcements ASX Limited Rialto Towers Level 45, 525 Collins Street MELBOURNE VIC 3000

Dear Sir/Madam

Mayne Pharma Group Limited - Change to option exercise price

On 4 October 2012, Mayne Pharma Group Limited ACN 115 832 963 ( Mayne Pharma ) announced an underwritten pro-rata accelerated non-renounceable entitlement offer of new Mayne Pharma ordinary shares ( Entitlement Offer ).

As a result of the Entitlement Offer, Mayne Pharma announces that in accordance with ASX Listing Rule 6.22, the exercise price of unquoted options issued to certain directors will be reduced by $0.0842 from 17 December 2012.

A summary of the revised exercise price of the unquoted options is set out in the table below.

Holder Date optiongranted Expiry date Exerciseprice Number Newexerciseprice
Mr I Scholes 29 October 2009 31 December 2012 $0.27 350,000 $0.1858
Hon R Best 29 October 2009 31 December 2012 $0.27 350,000 $0.1858
Mr B Mathieson 29 October 2009 31 December 2012 $0.27 350,000 $0.1858
Dr R Aston* 29 October 2009 31 December 2012 $0.27 1,900,000 $0.1858
Mr S Richards 13 February 2012 13 February 2019 $0.345 7,500,000 $0.2608

*Dr Roger Aston resigned from the board of directors of Mayne Pharma on 15 February 2012

Yours sincerely

==> picture [153 x 33] intentionally omitted <==

Mark Cansdale Company Secretary

Mayne Pharma Group Limited ABN | 76 115 832 963

a | Level 14, 474 Flinders St, Melbourne Victoria 3000, Australia t | +61 3 8614 7777 f | +61 3 9614 7022 | www.maynepharma.com